Cas:33018-91-6 Monoethyl pimelate manufacturer & supplier

Chemical Name:Monoethyl pimelate

CAS.NO:33018-91-6

Synonyms:Monoethyl Heptanedioate;BOC-HIS(TOS)-MBHA RESIN;BOC-L-HIS(TOS)-MBHA RESIN;heptanedioic acid monoethyl ester;6-(ethoxycarbonyl)hexanoic acid;PAM BOC-L-HISTIDINE (TOS);7-ethoxy 7-oxo heptanoic acid;Monoethyl PiMelate;BOC-HIS(TOS)-CMS RESIN;pimelicacidmonethylester;MFCD00801202;Pimelic Acid Monoethyl Ester;BOC-HIS(TOS)-BHA PS RESIN;Ethyl hydrogen pimelate;BOC-HIS(TOS)-BHA RESIN;EINECS 251-346-6;BOC-HIS(TOS)-PAM RESIN

Molecular Formula:C₉H₁₆O₄

Molecular Weight:188.22100

HS Code:2918990090

Physical and Chemical Properties:

Melting point:10ºC

Boiling point:135-138ºC 1mm

Density:1.074 g/cm3

Index of Refraction:1.442

PSA:63.60000

Exact Mass:188.10500

LogP:1.58460

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Monoethyl Heptanedioate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,BOC-HIS(TOS)-PAM RESIN physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,PAM BOC-L-HISTIDINE (TOS) Use and application,Monoethyl PiMelate technical grade,usp/ep/jp grade.

Related News: Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. Monoethyl pimelate manufacturer Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. Monoethyl pimelate supplier Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. Monoethyl pimelate vendor Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. Monoethyl pimelate factory Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data.